# Eli Lilly to Acquire Psychedelics Biotech AtaiBeckley for Up to $3.8 Billion

> ma · REPORTED · 2026-07-20

Eli Lilly agreed to acquire AtaiBeckley for $6.75 per share in cash representing approximately $2.8 billion upfront, plus contingent value rights worth up to $2.50 per share, for a total potential value near $3.8 billion. The deal targets AtaiBeckley's lead candidate BPL-003, an intranasal 5-MeO-DMT formulation for treatment-resistant depression.

About Eli Lilly: AtaiBeckley is a clinical-stage biotech developing psychedelic-based mental health therapies, including next-generation formulations of psychedelic compounds targeting treatment-resistant depression and other CNS disorders.

- Company: Eli Lilly
- Sector: mental health
- Primary source: https://www.lawrenceevans.com/2026/07/20/healthcare-news-deals-and-investments-update-july-20th-2026/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.